(somatrogon-ghla)
Table 2 includes a list of drugs with clinically significant drug interactions when administered concomitantly with NGENLA and instructions for preventing or managing them.
Replacement Glucocorticoid Treatment | |
Clinical Impact: | Microsomal enzyme 11β-hydroxysteroid dehydrogenase type 1 (11βHSD-1) is required for conversion of cortisone to its active metabolite, cortisol, in hepatic and adipose tissue. Growth hormone inhibits 11βHSD-1. Consequently, individuals with untreated GH deficiency have relative increases in 11βHSD-1 and serum cortisol. Initiation of NGENLA may result in inhibition of 11βHSD-1 and reduced serum cortisol concentrations. |
Intervention: | Patients treated with glucocorticoid replacement for hypoadrenalism may require an increase in their maintenance or stress doses following initiation of NGENLA [see Warnings and Precautions (5.7)]. |
Examples: | Cortisone acetate and prednisone may be affected more than others because conversion of these drugs to their biologically active metabolites is dependent on the activity of 11βHSD-1. |
Supraphysiologic Glucocorticoid Treatment | |
Clinical Impact: | Supraphysiologic glucocorticoid treatment may attenuate the growth-promoting effects of NGENLA in pediatric patients. |
Intervention: | Carefully adjust glucocorticoid replacement dosing in pediatric patients receiving glucocorticoid treatments to avoid hypoadrenalism and an inhibitory effect on growth. |
Cytochrome P450-Metabolized Drugs | |
Clinical Impact: | Limited published data indicate that growth hormone treatment increases cytochrome P450 (CYP450)-mediated antipyrine clearance. NGENLA may alter the clearance of compounds known to be metabolized by CYP450 liver enzymes. |
Intervention: | Careful monitoring is advisable when NGENLA is administered in combination with drugs metabolized by CYP450 liver enzymes. |
Oral Estrogen | |
Clinical Impact: | Oral estrogens may reduce the serum IGF-1 response to NGENLA. |
Intervention: | Patients receiving oral estrogen replacement may require higher NGENLA dosages. |
Insulin and/or Other Antihyperglycemic Agents | |
Clinical Impact: | Treatment with NGENLA may decrease insulin sensitivity, particularly at higher doses. |
Intervention: | Patients with diabetes mellitus may require adjustment of their doses of insulin and/or other antihyperglycemic agents [see Warnings and Precautions (5.4)]. |
| This Patient Information has been approved by the U.S. Food and Drug Administration. Revised: 04/2026 |
PATIENT INFORMATION (somatrogon-ghla) injection, for subcutaneous use |
What is NGENLA? |
Do not use NGENLA if:
|
Before using NGENLA, tell your child’s healthcare provider about all of your child’s medical conditions, including if your child:
Tell your child’s healthcare provider about all the medicines your child takes, including prescription and over-the-counter medicines, vitamins, and herbal supplements. NGENLA may affect how other medicines work, and other medicines may affect how NGENLA works. |
How should I use NGENLA?
|
What are the possible side effects of NGENLA? NGENLA may cause serious side effects, including:
The most common side effects of NGENLA include:
These are not all the possible side effects of NGENLA. You should tell your child’s healthcare provider if your child has any side effect that bothers them or that does not go away. |
How should I store NGENLA?
Before you use NGENLA pens for the first time (unused pens):
After you use NGENLA pens and there is still medicine left (up to 28 days of use):
Keep NGENLA and all medicines out of the reach of children. |
General information about the safe and effective use of NGENLA. Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Do not use NGENLA for a condition for which it was not prescribed. Do not give NGENLA to other people, even if they have the same symptoms because it may harm them. You can ask your pharmacist or healthcare provider for information about NGENLA that is written for health professionals. |
What are the ingredients in NGENLA? Active ingredient: somatrogon-ghla
|
Additional Resources
Chat online with Pfizer Medical Information regarding your inquiry on a Pfizer medicine or vaccine.
Speak with a Pfizer Medical Information Professional regarding your Pfizer medicine or vaccine inquiry.
Available 9AM-5PM ET Monday to Friday; excluding holidays.
Submit a medical question for a Pfizer medicine or a vaccine.
The submission will be reviewed during our standard business hours.
To report an adverse event related to a Pfizer product and you are not part of a clinical trial* for this medication, click the link below to submit your information:
Pfizer Safety Reporting Site
*If you are involved in a clinical trial for either product, adverse events should be reported to your coordinating study site.
If you cannot use the above website to report an adverse event related to a Pfizer medication, please call (800) 438-1985.
You may also contact the U.S. Food and Drug Administration (FDA) directly to report adverse events or product quality concerns either online at www.fda.gov/medwatch or by calling (800) 332-1088.